<DOC>
	<DOCNO>NCT00206674</DOCNO>
	<brief_summary>The purpose study evaluate Leukine induce clinical response remission patient Crohn 's disease .</brief_summary>
	<brief_title>Efficacy ( Induction Response/Remission ) Safety Study Patients With Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description>On 29 May 2009 , Bayer begin transition sponsorship trial Genzyme . NOTE : This study originally post sponsor Berlex , Inc. Berlex , Inc. rename Bayer HealthCare , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Stable active Crohn 's disease time screen Must able selfinject another person help injection Not colostomy ileostomy Not take prohibit medication define protocol Not GI surgery bowel obstruction last 6 month plan surgery next month Not ever take drug drug similar type past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Morbus Crohn</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Phase III</keyword>
	<keyword>Placebo Controlled</keyword>
</DOC>